/ /

Cheryl Guttman Krader
Cheryl Guttman Krader is a contributor to Dermatology Times, Ophthalmology Times, and Urology Times.
http://www.ophthalmologytimes.com http://www.urologytimes.com
Novel DME treatment derives from multimodal activity
ALG-1001 is an integrin receptor inhibitor that acts to stabilize the retina’s response to diabetes-related hypoxic and oxidative stress, mitigating production of a host of molecules involved in the development of diabetic macular edema.
Heads-up surgery: Current advantages debatable, but system offers opportunities for the future
Retinal specialists discuss the role of “heads-up” surgery.
New techniques centering on capsulotomy creation
Technologies and techniques such as femtosecond laser-assisted cataract surgery and microinvasive glaucoma surgery may be guiding the way for future cataract surgeries.
Focal, whole-gland cryo yield similar cancer control
Among men who are potent and have low-risk prostate cancer, focal cryotherapy appears to deliver similar oncologic control but with much better recovery of erectile function than a whole-gland approach, according to an analysis using data from the Cryo On-Line Data Registry.
Targeted Bx shows efficacy in surveillance cohort
After a median of 2 years in an active surveillance cohort being followed with multiparametric-magnetic resonance imaging and MRI-transrectal ultrasound fusion-guided biopsy (“targeted biopsy”), rates of biopsy-proven pathologic progression are similar among men with low-risk and intermediate-risk disease, say researchers from the National Institutes of Health.
Men who delay RP show no added risk of adverse pathology
After accounting for the risk of reclassification, carefully monitored men with favorable-risk prostate cancer who enroll in active surveillance and undergo delayed surgery are no more likely to demonstrate adverse features associated with 15-year prostate cancer-specific mortality than their counterparts who elect immediate curative treatment, say researchers from the Johns Hopkins University Brady Urological Institute, Baltimore.
Studies demonstrate testosterone’s CV safety, benefits
Two recently published studies significantly contribute to current knowledge regarding testosterone therapy and cardiovascular health, says one expert urologist.
Prostate Ca radiation therapy cost drivers analyzed
Prostate Ca radiation therapy cost drivers analyzed
The cost of radiation therapy for prostate cancer in the United States varies substantially, and most of the variation is accounted for by factors that are not related to the patient or tumor, according to the results of a study published online in Journal of Oncology Practice (Aug. 11, 2015).
Metformin/statin combo therapy reduces PCa mortality
Metformin/statin combo therapy reduces PCa mortality
Treatment with metformin plus a statin appears to pay huge dividends in high-risk prostate cancer patients, data from a large study show.
Best of AUA 2015: PCa surveillance, surgical controversies create buzz
Urology Times’ “Best of AUA 2015” report provides a guide to the meeting’s take-home messages in 15 therapeutic areas—an information-packed, condensed summary of the top papers and presentations.